Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, B-Cell 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 12Recurrence 11Burkitt Lymphoma 10Multiple Myeloma 7Lymphoma 7Neoplasms 6Leukemia, Myeloid, Acute 6Lymphoma, Mantle-Cell 5Leukemia 5Pancreatic Neoplasms 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Leukemia, B-Cell 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Simpson-Golabi-Behmel syndrome 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2

Interventions

Carboplatin 177Radiotherapy 139Cisplatin 110Pemetrexed 102Docetaxel 93Paclitaxel 92Gemcitabine 78Erlotinib Hydrochloride 73Magnetic Resonance Spectroscopy 72Radiosurgery 67Bevacizumab 65pembrolizumab 64Etoposide 60Blood Specimen Collection 60durvalumab 53Specimen Handling 48Nivolumab 48Surveys and Questionnaires 47Drug Therapy 41Standard of Care 35Radiation 33osimertinib 32atezolizumab 32Surgical Procedures, Operative 30Topotecan 29Irinotecan 29Gefitinib 29Educational Status 29Early Intervention, Educational 29Biopsy 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Neoplasms × Immunotherapy, Adoptive × Clear all
NCT03525782 2018-05-16

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

The First Affiliated Hospital of Guangdong Pharmaceutical University

Phase 1/2 Unknown
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡